Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Fermenta Biotech's Sloan Ratio for the quarter that ended in Sep. 2024 was 0.00%.
As of Sep. 2024, Fermenta Biotech has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Fermenta Biotech Sloan Ratio % Historical Data
The historical data trend for Fermenta Biotech's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Fermenta Biotech's Sloan Ratio %
For the Drug Manufacturers - Specialty & Generic subindustry, Fermenta Biotech's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fermenta Biotech's Sloan Ratio % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fermenta Biotech's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Fermenta Biotech's Sloan Ratio % falls into.
Fermenta Biotech Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Fermenta Biotech's Sloan Ratio for the fiscal year that ended in Mar. 2024 is calculated as
Fermenta Biotech's Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was 98.485 (Dec. 2023 ) + -69.407 (Mar. 2024 ) + -58.19 (Jun. 2024 ) + 113.796 (Sep. 2024 ) = ₹85 Mil.
Fermenta Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2024 was 0 (Dec. 2023 ) + 0 (Mar. 2024 ) + 0 (Jun. 2024 ) + 0 (Sep. 2024 ) = ₹0 Mil.
Fermenta Biotech's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 was 0 (Dec. 2023 ) + 0 (Mar. 2024 ) + 0 (Jun. 2024 ) + 0 (Sep. 2024 ) = ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fermenta Biotech (BOM:506414) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Sep. 2024, Fermenta Biotech has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Fermenta Biotech Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Fermenta Biotech's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Fermenta Biotech Ltd is engaged in the business of manufacturing and marketing chemicals, bulk drugs, enzymes, pharmaceutical formulations, and environmental solution products and renting and selling properties. It is a manufacturer and supplier of Vitamin D and also supplies Penicillin G Amidase, CAL B Lipase, Polymer Supports, and enzyme technologies. The company operates in two segments that are Property and Bulk Drugs/Chemicals. The majority of the revenue comes from the Bulk Drug/Chemicals segment. Geographically, it caters to both domestic and international markets and generates maximum revenue from the Indian market.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BOM:506414 has been successfully added to your 